OCT 22, 2020 7:00 AM PDT

Migraines: Dark Times and (Pharmaceutical) Rays of Hope

WRITTEN BY: Tara Fernandez


Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more prolonged and debilitating, encompassing a range of accompanying symptoms from throbbing pain and light sensitivity to nausea and vomiting. The pathophysiology of this condition is complex and identifying potential therapeutic targets has, for a long time, eluded neuroscientists. Among the challenges is that nobody knows what really causes migraines.

The current working theory is that the trigeminovascular system (a neural connection that innervates blood vessels in the head) is a major player. Recurrent activation and sensitization of this pathway alters the excitability of the brain, resulting in the hypersensitivity to light, sounds, and even smells. 

For the estimated 16 percent of the worldwide population that suffers from migraines, a silver lining has come in the form of a suite of migraine therapeutics that have recently entered the clinic. One of these is a migraine drug called erenumab (Aimovig) — a monoclonal antibody drug derived from natural immune systems. The antibody prevents both episodic as well as chronic migraines by blocking the activity of calcitonin gene-related peptide (CGRP), a potent peptide produced by neurons. Elevated levels of CGRP have been linked to a range of conditions including migraine, hypertension, and cardiac failure.

A recent study conducted by Australian scientists has highlighted the true potential of Erenumab at relieving severe migraine attacks in chronic sufferers. The study tracked migraine incidences in a cohort of almost 200 patients. After taking the drug, almost 60 percent of them had at least halved the number of migraines they experienced per month.

“These drugs represent a significant advance in migraine care, and with many patients describing them as ‘life-changing’, they bring new hope to many living with migraine disease,” said the study’s lead author Dr. Elspeth Hutton from Monash University.

Sources: Headache, AJMC, Nature.  


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 11, 2020
Drug Discovery & Development
Scientists Discover Key Gene Behind Antibiotic Resistance
AUG 11, 2020
Scientists Discover Key Gene Behind Antibiotic Resistance
Scientists from Oxford University have shown that a single gene can make some strains of Staphylococcus aureus (the bact ...
SEP 16, 2020
Immunology
Depression, but Not Anxiety, Causes Inflammation and Metabolic Imbalances
SEP 16, 2020
Depression, but Not Anxiety, Causes Inflammation and Metabolic Imbalances
Scientists have discovered that depressed individuals show higher levels of inflammation as well as elevated fat concent ...
SEP 17, 2020
Immunology
COVID Vaccine Works in Macaques - What about in Humans?
SEP 17, 2020
COVID Vaccine Works in Macaques - What about in Humans?
Pharmaceutical giant Pfizer, in partnership with BioNTech has reported that one of its lead vaccine candidates has shown ...
OCT 15, 2020
Immunology
The Immune Cells Giving Menopausal Women Higher BPs
OCT 15, 2020
The Immune Cells Giving Menopausal Women Higher BPs
In general, men have higher blood pressures than women, giving them an increased risk of developing heart disease. After ...
OCT 26, 2020
Immunology
Gearing up for Life: The First 7 Days of the Immune System
OCT 26, 2020
Gearing up for Life: The First 7 Days of the Immune System
The mother’s placenta serves as a shield for the developing fetus inside the womb, protecting it from the constant ...
NOV 06, 2020
Drug Discovery & Development
New Vaccine Shows Promise for Herpes
NOV 06, 2020
New Vaccine Shows Promise for Herpes
The World Health Organization estimates that over 500 million people have Herpes Simplex Virus Type 2 (HSV-2), a sexuall ...
Loading Comments...